BAM
CRBP icon

Bruderman Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Bruderman Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2
Closed – – 163
2017
Q2 		$0 Buy
+2
New +$392 ﹤0.01% 358

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bruderman Asset Management's CRBP Position: Q3 2017 in Review

Bruderman Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2017, closing a stake of 2 shares.

Bruderman Asset Management first reported a position in CRBP in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 69 funds tracked by Wall St. Rank hold CRBP as of Q3 2017.

  • Bruderman Asset Management reported no remaining Corbus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Bruderman Asset Management sold 2 Corbus Pharmaceuticals shares in Q3 2017.
  • Bruderman Asset Management first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Bruderman Asset Management's Corbus Pharmaceuticals position peaked at $0 in Q2 2017.
  • 69 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2017.

Based on Bruderman Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.